353 related articles for article (PubMed ID: 15232684)
1. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.
Ye JM; Dzamko N; Cleasby ME; Hegarty BD; Furler SM; Cooney GJ; Kraegen EW
Diabetologia; 2004 Jul; 47(7):1306-1313. PubMed ID: 15232684
[TBL] [Abstract][Full Text] [Related]
2. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
5. Lipid metabolism and insulin resistance in cirrhosis.
Kaye GL; Kruszynska YT; Harry DS; Heslop K; Johnston DG; McIntyre N
J Hepatol; 1994 Jun; 20(6):782-91. PubMed ID: 7930479
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
[TBL] [Abstract][Full Text] [Related]
7. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
[TBL] [Abstract][Full Text] [Related]
8. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
9. Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet.
Kuda O; Stankova B; Tvrzicka E; Hensler M; Jelenik T; Rossmeisl M; Flachs P; Kopecky J
J Physiol Pharmacol; 2009 Dec; 60(4):135-40. PubMed ID: 20065507
[TBL] [Abstract][Full Text] [Related]
10. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.
Oakes ND; Camilleri S; Furler SM; Chisholm DJ; Kraegen EW
Metabolism; 1997 Aug; 46(8):935-42. PubMed ID: 9258278
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
12. Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms.
Cleasby ME; Dzamko N; Hegarty BD; Cooney GJ; Kraegen EW; Ye JM
Diabetes; 2004 Dec; 53(12):3258-66. PubMed ID: 15561958
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance].
Zhao WH; Xiao JZ; Yang WY; Wang N; Wang X; Chen XP; Bu S
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3074-8. PubMed ID: 16324411
[TBL] [Abstract][Full Text] [Related]
14. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects.
James AP; Watts GF; Mamo JC
Diabetes Obes Metab; 2005 Jul; 7(4):381-9. PubMed ID: 15955124
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
[TBL] [Abstract][Full Text] [Related]
16. [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Chen XP; Yang WY; Bu S; Xiao JZ; Liu XL; Wang N; Zhao WH
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):280-3. PubMed ID: 15130413
[TBL] [Abstract][Full Text] [Related]
17. Crocetin improves the insulin resistance induced by high-fat diet in rats.
Sheng L; Qian Z; Shi Y; Yang L; Xi L; Zhao B; Xu X; Ji H
Br J Pharmacol; 2008 Jul; 154(5):1016-24. PubMed ID: 18469847
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
[TBL] [Abstract][Full Text] [Related]
19. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
[TBL] [Abstract][Full Text] [Related]
20. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
